Search
Cardiolipin Biosynthesis CL(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3(11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
smpdb.ca/view/SMP0288013MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition. It is essential for the optimal function of numerous enzymes that are involved in mitochondrial...
Cardiolipin Biosynthesis CL(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3(11Z,14Z,17Z))
smpdb.ca/view/SMP0288078MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition. It is essential for the optimal function of numerous enzymes that are involved in mitochondrial...
Duloxetine
go.drugbank.com/drugs/DB00476ApprovedInvestigationalDuloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. … [L6454] It has since received approval for a variety of indications including the treatment of neuropathic pain, Generalized Anxiety disorder, osteoarthritis, and stress incontinence.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: (3S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine, (S)-duloxetineFish oil
go.drugbank.com/drugs/DB13961ApprovedInvestigationalNutraceuticalFish oil is a component of SMOFLIPID, which was FDA approved in July 2016. … However, prescription-only fish oil products are sometimes prescribed for individuals who demonstrate severe (>= 500 mg/dL) hypertriglyceridemia [FDA Label].
Mixtures: OGAMIX(Evening primrose oil 500 mg, Lecithin oil 500 mg, Fish oil 125 mgand Vitamin E 10 mg Soft Gelatin Capsule), Hovid Omega-3 + 6Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesEthosuximide
go.drugbank.com/drugs/DB00593ApprovedInvestigationalAn anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingSynonyms: 2-ethyl-2-methylsuccinimide, (±)-2-ethyl-2-methylsuccinimideMebendazole
go.drugbank.com/drugs/DB00643ApprovedInvestigationalVet approvedA benzimidazole that acts by interfering with carbohydrate metabolism and inhibiting polymerization of microtubules. [PubChem]
Mixtures: L-OMBRIX-DUET, L-OMBRIX-DUETCategories: Heterocyclic Compounds, 2-RingNitroprusside
go.drugbank.com/drugs/DB00325ApprovedInvestigationalNitroprusside serves as a source of nitric oxide, a potent peripheral vasodilator that affects both arterioles and venules (venules more than arterioles). … Nitroprusside is often administered intravenously to patients who are experiencing a hypertensive emergency.
Categories: Compounds used in a research, industrial, or household settingProducts: NITROPRUSIATO DE SODIO 50 MG/2 ML INYECTABLE, Nitroprussid-Natrium AFTPharm 50 mg/2 ml InfusionslösungIdarucizumab
go.drugbank.com/drugs/DB09264ApprovedIdarucizumab protein structure can be viewed below, with disulfide bridges at the following points: H22-H95, H149-H205, H225-L-219, L23-L93, L139-L199. … Idarucizumab is a humanized monoclonal antibody fragment (Fab) derived from an immunoglobulin G1 isotype molecule that binds to and inactivates the oral anticoagulant dabigatran, thereby reversing its
Products: PRAXBİND 50 MG/ML ENJEKSİYONLUK/İNFÜZYONLUK ÇÖZELTİ, 2 ADET, PRAXBIND®Darifenacin
go.drugbank.com/drugs/DB00496ApprovedInvestigationalDarifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. … It is unknown if M3 receptor selectivity is clinically advantageous in overactive bladder syndrome treatments.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 InhibitorsSynonyms: (S)-1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-α,α-diphenyl-3-pyrrolidineacetamideEmicizumab
go.drugbank.com/drugs/DB13923ApprovedInvestigationalEmicizumab is a humanized recombinant monoclonal antibody that mimics the function of the coagulation Factor VIII and it has the capacity to bind simultaneously to activated Factor IX and Factor X. … Emicizumab was originated as an improved form of hBS23 and it was approved on November 16, 2017.[A31279, L1016] It was created by Chugai Pharmaceuticals Co.
Products: HEMLİBRA 60 MG/ 0.4 ML S.C. ENJEKSİYONLUK ÇÖZELTİ, 1 ADET, HEMLİBRA 150 MG/ 1 ML S.C. ENJEKSİYONLUK ÇÖZELTİ, 1 ADET